Amgen has expanded its operations into Brazil with the acquisition of Bergamo, a privately held Brazilian pharmaceutical company, for approximately $215 million. Amgen will also reacquire rights in Brazil to its products that were previously granted to Mantecorp (now Hypermarcas). Bergamo supplies medicines to hospitals in Brazil and has capabilities in oncology medicines as well as manufacturing facilities in Sao Paulo. Bergamo had revenues of $80 million in 2010. Under the agreement wi...